IRLAB Therapeutics
IRLAB | ST
Overview
Corporate Details
- ISIN(s):
- SE0012675361 (+1 more)
- LEI:
- 549300JAT34LHEI0DH60
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://irlab.se/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease. We have a well-defined, strategically focused R&D pipeline of powerful new treatments targeting the various stages of Parkinson’s as they worsen over time throughout the patient’s journey of neurodegeneration. Having a full range of effective disease management options for Parkinson’s patients is regarded as essential by both the medical and patient communities – and at the same time potentially a blockbuster pharmaceutical business.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-11 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämman 2025 i IRLAB Therapeutics AB
|
Swedish | 45.8 KB | |
| 2025-06-11 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB
|
English | 44.5 KB | |
| 2025-05-12 08:30 |
Declaration of Voting Results & Voting Rights Announcements
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB
|
Swedish | 65.6 KB | |
| 2025-05-12 08:30 |
Regulatory News Service
Notice to the Annual General Meeting in IRLAB Therapeutics AB
|
English | 38.5 KB | |
| 2025-05-07 07:00 |
Quarterly Report
|
Swedish | 380.2 KB | |
| 2025-05-07 07:00 |
Quarterly Report
|
English | 372.4 KB | |
| 2025-04-25 21:30 |
Annual Report
|
Swedish | 10.2 MB | |
| 2025-03-05 13:40 |
Earnings Release
IRLAB reports topline results from a Phase IIb study of pirepemat in patients w…
|
English | 54.9 KB | |
| 2025-03-05 13:40 |
Earnings Release
IRLAB rapporterar topline-resultat från en Fas IIb-studie med pirepemat i patie…
|
Swedish | 56.8 KB | |
| 2025-02-18 00:20 |
Capital/Financing Update
IRLAB strengthens its value creation capabilities through extended and expanded…
|
English | 52.2 KB | |
| 2025-02-18 00:20 |
Capital/Financing Update
IRLAB stärker sina möjligheter till värdeskapande genom förlängd och utökad lån…
|
Swedish | 52.8 KB | |
| 2025-02-12 07:00 |
Annual Report
|
Swedish | 371.1 KB | |
| 2025-02-12 07:00 |
Annual Report
|
English | 716.7 KB | |
| 2024-11-21 15:30 |
Regulatory News Service
Valberedningen utsedd inför IRLAB:s årsstämma 2025
|
Swedish | 41.7 KB | |
| 2024-11-21 15:30 |
Regulatory News Service
Nomination committee appointed for IRLAB’s annual general meeting 2025
|
English | 41.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2020-12-23 | Viktor Siewertz | Other | Buy | 7,500 | 327,750.00 SEK |
| 2020-03-13 | Gunnar Olof Olsson | Other | Buy | 2,000 | 36,920.00 SEK |
| 2020-02-26 | Hans Olov Sören Olsson | Other | Other | 12,500 | 337,500.00 SEK |
| 2020-02-26 | Anders Vedin | Other | Buy | 7,238 | 205,559.20 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |